• Latest
  • Trending
WHO, partners seek $23.4 BLN for new Covid war chest

WHO, partners seek $23.4 BLN for new Covid war chest

Global economies struggle as oil supplies tighten, volatile stakes

Oil prices see a surge, supply concerns to aid in the cause

S & P 500 ends at record high as Wall Street rises

Wall St futures tumble, dollar holds its ground against tides

OPEC+ members face issues of tight oil supplies

OPEC+ members face issues of tight oil supplies

U.S. energy companies shudder after economic and climate warnings

U.S. energy companies shudder after economic and climate warnings

People’s Bank and CA Sri Lanka to offer SME Mentoring Program

People’s Bank strikes Gold at Technnovation Awards 2022

Russia evades default through sheer force of will; Kremlin speaks

Russia evades default through sheer force of will; Kremlin speaks

Global economies struggle as oil supplies tighten, volatile stakes

G7 fixate on stricter sanctions to impose on Russia, oil rates wobble

People’s Bank and CA Sri Lanka to offer SME Mentoring Program

People’s Bank empowers local youth with People’s Spark Entrepreneurship Development Programme

People’s Bank and CA Sri Lanka to offer SME Mentoring Program

People’s Bank and CA Sri Lanka to offer SME Mentoring Program

Russia may be driven into default, Eurobonds due in payment

Russia may be driven into default, Eurobonds due in payment

Asia shares falls on worries over inflation, Fed outlook

An insightful glimpse of the market during the inflation period

Russia’s Sovcomflot managed to strike deals despite sanctions

Russia’s Sovcomflot managed to strike deals despite sanctions

Global Business Review Magazine
Wednesday, July 6, 2022
Nominate Here
  • Home
  • Banking
  • Finance
  • Technology
  • FinTech
  • Business
  • Videos
  • Events
  • Awards
  • Magazine
No Result
View All Result
Global Business Review Magazine
No Result
View All Result

WHO, partners seek $23.4 BLN for new Covid war chest

WHO, partners seek $23.4 BLN for new Covid war chest

The World Health Organization (WHO) and other aid groups appealed to leaders of the world’s 20 biggest economies to fund a $23.4 billion plan to bring COVID-19 vaccines, tests and drugs to poorer countries. WHO Director-General Tedros Adhanom Ghebreyesus said that the Group of 20, whose leaders are meeting in Rome, had the political and financial power needed to end the pandemic by funding the plan.

The latest update of the so-called Access to COVID-19 Tools Accelerator (ACT-A), until September 2022, is expected to include use of an experimental oral antiviral pill, which is made by Merck & Co for treating mild and moderate cases. If the pill is approved by regulatory authorities, the cost could be as little as $10 per course. Carl Bildt, WHO Special Envoy to the ACT-Accelerator, told reporters that the request is for $23.4 billion. Bildt, a former Swedish prime minister, acknowledged that the ACT-A has struggled to secure previous financing.

YOU MAY ALSO LIKE

Oil prices see a surge, supply concerns to aid in the cause

OPEC+ members face issues of tight oil supplies

Norwegian Prime Minister Jonas Gahr Stoere, told the media that he is hoping and urging that the G20 will make a commitment to end the pandemic. Equal budgets of $7 billion are earmarked for both vaccines and diagnostic tests. $5.9 billion for boosting health systems and $3.5 billion for treatments including antivirals, corticosteroids, and medical oxygen. COVAX, the vaccines arm of the ACT-A, has delivered some 400 million COVID-19 doses to more than 140 low- and middle-income countries, said WHO chief scientist Soumya Swaminathan. About 82 countries are likely to miss a WHO global target of 40% vaccination coverage by year-end.

Swaminathan added that one of the things that is now interfering in a big way is the need for boosters. Nearly a million booster jabs are being given each day, which is three times the amount of vaccines being administered in low-income countries. The U.S. Food and Drug Administration is considering emergency use authorization of molnupiravir, the antiviral pill Merck has developed with Ridgeback Biotherapeutics. Maria van Kerkhove, the WHO’s technical lead on COVID said that this is a drug that they are currently evaluating and met with Merck. And that is to discuss data from their current clinical trials that are under way in other countries.

Tags: businessHealthcareWorld Health Organization
ShareTweetShare

Search

No Result
View All Result

Recent News

Global economies struggle as oil supplies tighten, volatile stakes

Oil prices see a surge, supply concerns to aid in the cause

S & P 500 ends at record high as Wall Street rises

Wall St futures tumble, dollar holds its ground against tides

OPEC+ members face issues of tight oil supplies

OPEC+ members face issues of tight oil supplies

U.S. energy companies shudder after economic and climate warnings

U.S. energy companies shudder after economic and climate warnings

People’s Bank and CA Sri Lanka to offer SME Mentoring Program

People’s Bank strikes Gold at Technnovation Awards 2022

Russia evades default through sheer force of will; Kremlin speaks

Russia evades default through sheer force of will; Kremlin speaks

Global Business Review Magazine

Global Business Review is a online print magazine focusing on the updates and information about on emerging markets, Finance, Banking, Technology. Global Business Review provides news, features, analysis, commentary, and interviews from industry across the globe.

Recent News

  • Oil prices see a surge, supply concerns to aid in the cause
  • Wall St futures tumble, dollar holds its ground against tides
  • OPEC+ members face issues of tight oil supplies
  • U.S. energy companies shudder after economic and climate warnings
  • People’s Bank strikes Gold at Technnovation Awards 2022

Categories

  • Banking
  • Business
  • Events
  • Finance
  • FinTech
  • Tech
  • Videos
  • About
  • Nominate
  • Privacy & Policy

© 2022 Global Business Review Magazine - All Rights Reserved.

No Result
View All Result
  • Home
  • Banking
  • Finance
  • Technology
  • FinTech
  • Business
  • Videos
  • Events
  • Awards
  • Magazine

© 2022 Global Business Review Magazine - All Rights Reserved.

Go to mobile version